JKJelena Kolic

Jelena Kolic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jelena Kolic has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ProteoAnalyst : Connecting biological context and peptide‐level evidence in quantitative proteomics and phosphoproteomics

    by Guangyan Zhou, Gordon Li, Danielle M. Simons, Alyssa Weinrauch, Nolan Sammut, Jelena Kolic, Haoning Howard Cen, Daina Avizonis, Peter Siegel, Francis C. Lynn, et al.

    Modern mass spectrometry now routinely quantifies thousands of proteins and phosphosites. While raw spectral processing and quantification have matured over the past few years, downstream statistical analysis and functional interpretation remain challenging. Current tools are often fragmented across separate applications for statistics, enrichment, network analysis, and phosphoproteomics. Furthermore, they operate largely at the protein or site level, leaving the supporting peptide, precursor, and phosphosite measurements out of reach; while pathway and network visualizations are provided without subcellular context. To address these limitations, we developed ProteoAnalyst, an easy‐to‐use web‐based platform that takes common upstream outputs (MaxQuant, FragPipe, DIA‐NN, and Spectronaut) through quality control, statistical analysis, and functional interpretation within a single environment. Researchers can navigate from pathways, compartment‐aware interaction networks, and kinase‐substrate networks down to the individual proteins, peptides, precursors, and phosphosites that support them. Dedicated modules extend this capacity to peptide‐level detection of isoform usage and post‐translational modification (PTM) relative fractions, phosphoproteomics with protein abundance correction, and biomarker analysis. Our benchmarks and case studies demonstrate that ProteoAnalyst integrates well‐established methods with rich functional analysis and visualization to streamline data interpretation and hypothesis generation. ProteoAnalyst is freely available at www.proteoanalyst.ca .

  • Open Access

    Persistent organic pollutant concentrations in human pancreas correlate with markers of beta cell dysfunction

    by Myriam P. Hoyeck, Ma. Enrica Angela Ching, Jana Palaniyandi, Evgenia Fadzeyeva, Jelena Kolic, Jillian Ashley-Martin, James Lyon, Nancy Smith, Erin E. Mulvihill, James D. Johnson, et al.

    Epidemiological studies consistently report associations between circulating concentrations of persistent organic pollutants and increased type 2 diabetes risk. Measures of pollutant concentrations in pancreas are limited; given the role of the endocrine pancreas in diabetes pathogenesis, this is an important gap in the literature. Additionally, no studies have correlated pollutant concentrations with direct measures of human beta cell function. We measure concentrations from 3 pollutant classes—dioxins/furans, polychlorinated biphenyls, and organochlorine pesticides—in pancreas and peripancreatic adipose tissue biopsies obtained from 31 human organ donors. We show that pollutants are consistently detected in human pancreas, and for some analytes, at higher concentrations than in adipose. We next assess correlations between pollutant concentrations and systemic indicators of diabetes risk (body mass index, age, and haemoglobin A1c) and direct measures of beta cell function in isolated islets from the same 31 donors. Pancreas polychlorinated biphenyls and organochlorine pesticides positively correlate with body mass index, age and basal insulin secretion but negatively correlate with stimulation index (ratio of insulin secretion under high glucose / low glucose conditions). Pancreas dioxins/furans positively correlate with fatty acid- and amino acid-stimulated insulin secretion. These data indicate that lipophilic pollutants accumulate in human pancreas and positively correlate with surrogate markers of diabetes risk.


  • Open Access

    Proteomic predictors of individualized nutrient-specific insulin secretion in health and disease

    by Jelena Kolic, WenQing Grace Sun, Haoning Howard Cen, Jessica D. Ewald, Jason C. Rogalski, Shugo Sasaki, Han Sun, Varsha Rajesh, Yi Han Xia, Renata Moravcova, et al.


  • Open Access

    Beta-Hydroxybutyrate Promotes Basal Insulin Secretion While Decreasing Glucagon Secretion in Mouse and Human Islets

    by Risha Banerjee, Ying Zhu, George P Brownrigg, Renata Moravcova, Jason C Rogalski, Leonard J Foster, James D Johnson, Jelena Kolic

    Dietary carbohydrates raise blood glucose levels, and limiting carbohydrate intake improves glycemia in patients with type 2 diabetes. Low carbohydrate intake (< 25 g) allows the body to utilize fat as its primary fuel. As a consequence of increased fatty acid oxidation, the liver produces ketones to serve as an alternative energy source. β-Hydroxybutyrate (βHB) is the most abundant ketone. While βHB has a wide range of functions outside of the pancreas, its direct effects on islet cell function remain understudied. We examined human islet secretory response to acute racemic βHB treatment and observed increased insulin secretion at a low glucose concentration of 3 mM. Because βHB is a chiral molecule, existing as both R and S forms, we further studied insulin and glucagon secretion following acute treatment with individual βHB enantiomers in human and C57BL/6J mouse islets. We found that acute treatment with R-βHB increased insulin secretion and decreased glucagon secretion at physiological glucose concentrations in both human and mouse islets. Proteomic analysis of human islets treated with R-βHB over 72 hours showed altered abundance of proteins that may promote islet cell health and survival. Collectively, our data show that physiological concentrations of βHB influence hormone secretion and signaling within pancreatic islets.


  • Open Access

    Proteomic predictors of individualized nutrient-specific insulin secretion in health and disease

    by Jelena Kolic, WenQing Grace Sun, Haoning Howard Cen, Jessica Ewald, Jason C. Rogalski, Shugo Sasaki, Han Sun, Varsha Rajesh, Yi Han Xia, Renata Moravcova, et al.

    Population level variation and molecular mechanisms behind insulin secretion in response to carbohydrate, protein, and fat remain uncharacterized despite ramifications for personalized nutrition. Here, we define prototypical insulin secretion dynamics in response to the three macronutrients in islets from 140 cadaveric donors, including those diagnosed with type 2 diabetes. While islets from the majority of donors exhibited the expected relative response magnitudes, with glucose being highest, amino acid moderate, and fatty acid small, 9% of islets stimulated with amino acid and 8% of islets stimulated with fatty acids had larger responses compared with high glucose. We leveraged this insulin response heterogeneity and used transcriptomics and proteomics to identify molecular correlates of specific nutrient responsiveness, as well as those proteins and mRNAs altered in type 2 diabetes. We also examine nutrient-responsiveness in stem cell-derived islet clusters and observe that they have dysregulated fuel sensitivity, which is a hallmark of functionally immature cells. Our study now represents the first comparison of dynamic responses to nutrients and multi-omics analysis in human insulin secreting cells. Responses of different people’s islets to carbohydrate, protein, and fat lay the groundwork for personalized nutrition. ONE-SENTENCE SUMMARY Deep phenotyping and multi-omics reveal individualized nutrient-specific insulin secretion propensity.


  • Open Access

    Beta-cell specific Insr deletion promotes insulin hypersecretion and improves glucose tolerance prior to global insulin resistance

    by Søs Skovsø, Evgeniy Panzhinskiy, Jelena Kolic, Haoning Howard Cen, Derek A. Dionne, Xiao-Qing Dai, Rohit B. Sharma, Lynda Elghazi, Cara E. Ellis, Katharine Faulkner, et al.

    Insulin receptor (Insr) protein is present at higher levels in pancreatic β-cells than in most other tissues, but the consequences of β-cell insulin resistance remain enigmatic. Here, we use an Ins1cre knock-in allele to delete Insr specifically in β-cells of both female and male mice. We compare experimental mice to Ins1cre-containing littermate controls at multiple ages and on multiple diets. RNA-seq of purified recombined β-cells reveals transcriptomic consequences of Insr loss, which differ between female and male mice. Action potential and calcium oscillation frequencies are increased in Insr knockout β-cells from female, but not male mice, whereas only male βInsrKO islets have reduced ATP-coupled oxygen consumption rate and reduced expression of genes involved in ATP synthesis. Female βInsrKO and βInsrHET mice exhibit elevated insulin release in ex vivo perifusion experiments, during hyperglycemic clamps, and following i.p. glucose challenge. Deletion of Insr does not alter β-cell area up to 9 months of age, nor does it impair hyperglycemia-induced proliferation. Based on our data, we adapt a mathematical model to include β-cell insulin resistance, which predicts that β-cell Insr knockout improves glucose tolerance depending on the degree of whole-body insulin resistance. Indeed, glucose tolerance is significantly improved in female βInsrKO and βInsrHET mice compared to controls at 9, 21 and 39 weeks, and also in insulin-sensitive 4-week old males. We observe no improved glucose tolerance in older male mice or in high fat diet-fed mice, corroborating the prediction that global insulin resistance obscures the effects of β-cell specific insulin resistance. The propensity for hyperinsulinemia is associated with mildly reduced fasting glucose and increased body weight. We further validate our main in vivo findings using an Ins1-CreERT transgenic line and find that male mice have improved glucose tolerance 4 weeks after tamoxifen-mediated Insr deletion. Collectively, our data show that β-cell insulin resistance in the form of reduced β-cell Insr contributes to hyperinsulinemia in the context of glucose stimulation, thereby improving glucose homeostasis in otherwise insulin sensitive sex, dietary and age contexts.


  • Open Access

    Differential effects of voclosporin and tacrolimus on insulin secretion from human islets

    by Jelena Kolic, Leanne Beet, Peter Overby, Haoning Howard Cen, Evgeniy Panzhinskiy, Daren R. Ure, Jennifer L. Cross, Robert B. Huizinga, James D. Johnson

    Context: The incidence of new onset diabetes after transplant (NODAT) has increased over the past decade, likely due to calcineurin inhibitor-based immunosuppressants, including tacrolimus (TAC) and cyclosporin (CsA). Voclosporin (VCS), a next generation calcineurin inhibitor is reported to cause fewer incidences of NODAT but the reason is unclear. Objective: Whilst calcineurin signaling plays important roles in pancreatic β-cell survival, proliferation, and function, its effects on human β-cells remain understudied. In particular, we do not understand why some calcineurin inhibitors have more profound effects on the incidence of NODAT. Methods: We compared the effects of TAC and VCS on the dynamics of insulin secretory function, programmed cell death rate, and the transcriptomic profile of human islets. We studied two clinically relevant doses of TAC (10 ng/ml, 30 ng/ml) and VCS (20 ng/ml, 60 ng/ml), meant to approximate the clinical trough and peak concentrations. Results: TAC, but not VCS, caused a significant impairment of 15 mM glucose-stimulated and 30 mM KCl-stimulated insulin secretion. This points to molecular defects in the distal stages of exocytosis after voltage-gated Ca 2+ entry. No significant effects on islet cell survival or total insulin content were identified. RNA sequencing showed that TAC significantly decreased the expression of 17 genes, including direct and indirect regulators of exocytosis ( SYT16 , TBC1D30 , PCK1 , SMOC1 , SYT5, PDK4 , and CREM ), whereas VCS has less broad and milder effects on gene expression. Conclusions: Clinically relevant doses of TAC, but not VCS, directly inhibit insulin secretion from human islets, likely via transcriptional control of exocytosis machinery.